Core Viewpoint - NAYA Biosciences supports the U.S. President's executive order aimed at reducing IVF costs and expanding access to fertility services, which is expected to significantly lower out-of-pocket expenses for families dealing with infertility [1][3]. Company Overview - NAYA Biosciences is a life science portfolio company focused on breakthrough treatments in oncology, autoimmune diseases, and women's health, with a particular emphasis on fertility services [7]. - The company operates fertility-focused clinics through its subsidiary INVO Centers, LLC, and currently has two operational INVO Centers in the U.S. along with a conventional IVF clinic [5]. Fertility Treatment Innovations - NAYA's INVOcell device is the first FDA-cleared in vivo Intravaginal Culture (IVC) system in the U.S., offering a more natural and economical fertility treatment compared to conventional IVF methods [6]. - The INVOcell procedure utilizes the woman's vagina as an incubator for embryo development, which is believed to provide a safer and more effective treatment option [6]. Industry Context - The high cost of IVF and lack of comprehensive insurance coverage for fertility services in most states create significant financial barriers for individuals and couples struggling with infertility [2]. - Currently, fewer than 20 states mandate some level of fertility coverage, leaving millions without insurance assistance, highlighting the importance of the administration's actions to address these cost concerns [3]. Commitment to Accessibility - NAYA is committed to advocating for policies that support individuals and families seeking fertility treatments, aiming to ensure that every hopeful parent has the opportunity to build a family [4].
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment